CVMHealthcare · BiotechnologyThe 2 Wall Street analysts covering CEL-SCI Corp. hold a median 12-month price target of $13 — +780.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 34 of 100 as at 21 Aug 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores CEL-SCI Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (87): Smaller than most of the companies we track.
Momentum (5): The shares have been drifting down relative to others.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on CVM, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +780.3% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 12 July 2023 | EF Hutton | Reiterates | Buy | — |
| 9 Mar 2023 | EF Hutton | Reiterates | Buy | — |
| 17 Feb 2023 | EF Hutton | Assumes | Buy | $10 |
| 29 Dec 2022 | EF Hutton | Maintains | Buy | — |
| 25 Aug 2022 | EF Hutton | Initiates | Buy | — |
| 7 Apr 2022 | EF Hutton | Initiates | Buy | — |
| 13 Jan 2020 | H.C. Wainwright | Initiates | Buy | — |
| 13 Jan 2020 | HC Wainwright & Co. | Initiates | Buy | — |
| 20 Feb 2013 | Taglich Brothers | Initiates | Speculative Buy | — |
| 13 Feb 2013 | Chardan Capital | Initiates | Buy | — |
| 14 Jan 2013 | Laidlaw & Co. | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CVM appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 78% of US stocks
Cheaper than 42% of US stocks
Cheaper than 68% of US stocks
Higher than 32% of US stocks
Higher than 30% of US stocks
Higher than 6% of US stocks
Higher than 5% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own CEL-SCI Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
CEL-SCI announced its financial results for the three months ended June 30, 2026, in its fiscal third quarter report. The company also provided an update on recent corporate and clinical developments related to its lead candidate, Multikine.
Why it matters — CVM watchers monitor these quarterly results and clinical updates to track progress on Multikine and the company's financial standing.
A study on CEL-SCI's Multikine immunotherapy was published in the peer-reviewed journal Oral Oncology, supporting the company's biomarker strategy and suggesting a potential overall survival benefit ahead of a confirmatory registration study in head and neck cancer.
Why it matters — Peer-reviewed publication of data supporting Multikine's biomarker strategy adds scientific credibility as CEL-SCI prepares for its confirmatory registration study in head and neck cancer.
CEL-SCI announced that a leading oncology journal has accepted for publication new Phase 3 data on its investigational drug Multikine, demonstrating an overall survival benefit in underserved head and neck cancer patients.
Why it matters — A peer-reviewed publication of Phase 3 data showing a survival benefit could lend scientific credibility to Multikine and support the company's regulatory and commercial efforts.
The 2 Wall Street analysts covering CEL-SCI Corp. have a median 12-month price target of $13, with estimates ranging from $10 to $15. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 2 analysts covering CEL-SCI Corp., 2 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks CEL-SCI Corp. 34 out of 100 across roughly 4,600 US stocks as at 21 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 21 Aug 2026, CEL-SCI Corp. ranks 34 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (87 of 100).
No one can know that. What the data says: the median 12-month target from 2 analysts implies +780.3% from the last close, and Ticker Nerd's factor model ranks CEL-SCI Corp. 34 out of 100 as at 21 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering CEL-SCI Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CVM are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $10 to $15 over the next 12 months.
CEL-SCI Corp. returned -84.5% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
CEL-SCI Corporation is a biotechnology company specialized in the research and development of immunotherapy products aimed at treating cancer, autoimmune, and infectious diseases. Founded in 1983, the company focuses on activating the immune system to combat illnesses, with its flagship product, Multikine, targeting significant cancer treatment needs.
The most recent item we track (Business Wire, 17 Aug 2026): "CEL-SCI Reports Fiscal Third Quarter 2026 Results". CEL-SCI announced its financial results for the three months ended June 30, 2026, in its fiscal third quarter report. The company also provided an update on recent corporate and clinical developments related to its lead candidate, Multikine.
CEL-SCI Corporation is a biotechnology company specialized in the research and development of immunotherapy products aimed at treating cancer, autoimmune, and infectious diseases. Founded in 1983, the company focuses on activating the immune system to combat illnesses, with its flagship product, Multikine, targeting significant cancer treatment needs. CEL-SCI combines drug discovery, development, and manufacturing of complex biological substances, playing a prominent role in advancing immune-based therapeutic approaches. It serves a global healthcare market by addressing unmet medical needs through innovative immunotherapy solutions.
CEO Mr. Geert R. Kersten Esq. · United States · https://cel-sci.com